Franchi Jean M. 4

4 · Disc Medicine, Inc. · Filed Feb 19, 2026

AI-generated summary of this filing

Updated Feb 19, 2026

Disc Medicine CFO Jean M. Franchi Sells Shares

What Happened

Jean M. Franchi, Chief Financial Officer of Disc Medicine (IRON), sold a total of 11,156 shares in open-market transactions on Feb 17–18, 2026, generating roughly $719,728 in proceeds. The individual transactions were: 4,075 shares at $62.86 on 2026-02-17 ($256,155); 3,397 shares at a weighted average price of $65.01 on 2026-02-18 ($220,838); and 3,684 shares at a weighted average price of $65.89 on 2026-02-18 (~$242,735). These were sales (not purchases), which for insiders are often routine.

Key Details

Transaction dates and prices:
- 2026-02-17: 4,075 shares @ $62.86 = $256,155 (sale)
- 2026-02-18: 3,397 shares @ weighted avg $65.01 = $220,838 (sale; prices ranged $64.47–$65.45)
- 2026-02-18: 3,684 shares @ weighted avg $65.89 = $242,735 (sale; prices ranged $65.51–$66.38)
Total shares sold: 11,156; total proceeds: approx. $719,728.
Shares owned after transaction: Not specified in the provided filing excerpt.
Notable footnotes:
- One sale (Feb 17) was a "sell-to-cover" to satisfy tax withholding on vested restricted stock units (not a discretionary sale).
- The Feb 18 sales were effected under a Rule 10b5-1 trading plan adopted Sept 25, 2025.
- The Feb 18 prices reported are weighted averages; the filing notes the per-trade price ranges and offers to provide per-price breakdowns on request.
Filing timeliness: Report filed Feb 19, 2026 — generally within Form 4’s required filing window for these Feb 17–18 transactions (no late-filing indication in provided data).

Context

These transactions are sales, including a tax-withholding sale tied to RSU vesting and trades under a pre-established 10b5-1 plan. Such sales are commonly routine and do not by themselves indicate management sentiment about the company’s prospects.

Form 4

Period: 2026-02-17

Chief Financial Officer

Transactions

Footnotes (4)

[F1]This transaction represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of certain restricted stock units previously reported in Table I. This sale is a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
[F2]These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on September 25, 2025.
[F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.47 to $65.45, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (3) and (4) to this Form 4.
[F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.51 to $66.38, inclusive.

Signature

By: /s/ Rahul Khara, as Attorney-in-Fact|2026-02-19

1 file